| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/05/2009 | US20090062257 Deuterium-enriched varenicline |
| 03/05/2009 | US20090062256 LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
| 03/05/2009 | US20090062254 Acute Treatment of Headache with Phenothiazine Antipsychotics |
| 03/05/2009 | US20090062253 Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| 03/05/2009 | US20090062252 Therapeutic isoxazole compounds |
| 03/05/2009 | US20090062248 Optimizing mifepristone levels in plasma serum of patients suffering from mental disorders treatable with glucocorticoid receptor antagonists |
| 03/05/2009 | US20090062238 Method for treatment of neuropathic pain |
| 03/05/2009 | US20090062213 Small Molecule Inhibitors of PDZ Interactions |
| 03/05/2009 | US20090062212 Peptide analogs that are potent and selective for human neurotensin preceptor subtype 2 |
| 03/05/2009 | US20090062199 Nogo Receptor Polypeptides and Polypeptide Fragments and Uses Thereof |
| 03/05/2009 | US20090062198 Maurotoxin, PI1 and HSTX1 derivatives |
| 03/05/2009 | US20090062180 Polypeptide biodrugs with given amino acid sequence which includes phosphorylated serine or threonine conjugated to a hydrophobic moiety such as a fatty acid; treating disorders such as Type II Diabetes, neurodegenerative diseases and psychological disorders |
| 03/05/2009 | US20090061011 Compositions and methods for delivery of poorly soluble drugs |
| 03/05/2009 | US20090060953 Methods for using tetanus toxin for beneficial purposes in animals (mammals) |
| 03/05/2009 | US20090060925 Rage Fusion Proteins and Methods of Use |
| 03/05/2009 | US20090060918 Method of treating or preventing an IL-1 related disease or condition |
| 03/05/2009 | US20090060900 Methods for Screening Compounds That Modulate Lipid Metabolism |
| 03/05/2009 | US20090060899 Composition of organic compounds |
| 03/05/2009 | US20090060895 Compositions and Methods of Using Chondroitinase ABCI Mutants |
| 03/05/2009 | US20090060873 Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris |
| 03/05/2009 | US20090060865 Mammalian receptor proteins; related reagents and methods |
| 03/05/2009 | US20090060848 Pharmaceutical composition which reduces or eliminates drug abuse potential |
| 03/05/2009 | DE102007040336A1 Neue Inhibitoren der 5-Lipoxygenase und deren Verwendungen New inhibitors of 5-lipoxygenase and their uses |
| 03/05/2009 | CA2698129A1 Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
| 03/05/2009 | CA2698071A1 Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| 03/05/2009 | CA2698013A1 Protein kinase c-d inhibitors that protect against cellular injury and inflammation and promote astrocyte proliferation |
| 03/05/2009 | CA2697990A1 Medication combinations for the treatment of alcoholism and drug addiction |
| 03/05/2009 | CA2697688A1 Catecholamine derivatives and prodrugs thereof |
| 03/05/2009 | CA2697382A1 4-(4-pyridinyl)-benzamides and their use as rock activity modulators |
| 03/05/2009 | CA2697167A1 Benzimidazole derivatives used as fxr agonists |
| 03/05/2009 | CA2696609A1 Therapeutic isoxazole compounds |
| 03/05/2009 | CA2696594A1 Liquid formulation of g-csf conjugate |
| 03/05/2009 | CA2695822A1 A combination treatment |
| 03/05/2009 | CA2695559A1 Neuroprotection using nap-like and sal-like peptide mimetics |
| 03/05/2009 | CA2694911A1 Substituted piperazinyl pyrazines and pyridines as 5-ht7 receptor antagonists |
| 03/05/2009 | CA2691961A1 Catecholamine derivatives and prodrugs thereof |
| 03/04/2009 | EP2031062A1 Dna encoding polypeptide capable of modulating muscle-specific tyrosine kinase activity |
| 03/04/2009 | EP2031057A1 SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME |
| 03/04/2009 | EP2030970A1 Allosteric modulators of metabotropic glutamate receptors |
| 03/04/2009 | EP2030622A1 Dosage regimen for the treatment of a traumatic brain injury with progesterone |
| 03/04/2009 | EP2030619A1 Use of dopamine stabilizers |
| 03/04/2009 | EP2030617A1 Use of tranilast and derivatives thereof for the therapy of neurological conditions |
| 03/04/2009 | EP2030615A2 Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
| 03/04/2009 | EP2029607A1 Novel 8,10-diaza-bicycloý4.3.1¨decane derivatives and their medical use |
| 03/04/2009 | EP2029603A1 Pyrrolo[3,2-d]pyrimidin-4-one derivative as myeloperoxidase inhibitor |
| 03/04/2009 | EP2029600A1 Substituted pteridines substituted with a four-membered heterocycle |
| 03/04/2009 | EP2029598A1 2-thioxanthine derivatives acting as mpo-inhibitors |
| 03/04/2009 | EP2029596A2 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same |
| 03/04/2009 | EP2029595A1 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivative and its medical use |
| 03/04/2009 | EP2029594A1 Novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives and their medical use |
| 03/04/2009 | EP2029588A2 Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
| 03/04/2009 | EP2029577A2 Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline |
| 03/04/2009 | EP2029564A2 Treatment for depressive disorders |
| 03/04/2009 | EP2029561A1 Tricyclic compound and pharmaceutical use thereof |
| 03/04/2009 | EP2029559A1 Aryl-4-ethynyl-isoxazole derivatives |
| 03/04/2009 | EP2029553A1 Substituted pyrazinone derivatives for use as a medicine |
| 03/04/2009 | EP2029550A2 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands |
| 03/04/2009 | EP2029548A1 Sulphur containing pyrazole derivatives as selective cannabinoid cb1 receptor antagonists |
| 03/04/2009 | EP2029544A1 Pyrrolidine derivatives useful as bace inhibitors |
| 03/04/2009 | EP2029537A1 Bicyclic tetrahydropyrrole compounds |
| 03/04/2009 | EP2029536A1 Bicyclic tetrahydropyrrole compounds |
| 03/04/2009 | EP2029535A1 Isoindole derivatives useful for treating pain, gastrointestinal diseases and cancer |
| 03/04/2009 | EP2029164A2 Anti-leukocyte recruitment therapy for the treatment of seizures and epilepsy |
| 03/04/2009 | EP2029145A2 Pyrrolopyrimidine compounds and their uses |
| 03/04/2009 | EP2029139A1 Use of a p38 kinase inhibitor for treating psychiatric disorders |
| 03/04/2009 | EP2029136A1 Treatment for depressive disorders |
| 03/04/2009 | EP2029130A2 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
| 03/04/2009 | EP2029117A2 Rapid dissolution of combination products |
| 03/04/2009 | EP2029100A2 Ache-nmda combination wafer |
| 03/04/2009 | EP2029097A2 Combination antidepressants wafer |
| 03/04/2009 | EP1928458B1 Use of inhibitors of the na+/h+ exchanger, subtype 5 (nhe5), to improve memory retention |
| 03/04/2009 | EP1869049B1 Imidazopyridazine compounds |
| 03/04/2009 | EP1833795B1 Pyridine compounds for the treatment of prostaglandin mediated diseases |
| 03/04/2009 | EP1776343B1 Quinoline derivatives as neurokinin receptor antagonists |
| 03/04/2009 | EP1740198A4 Anti-aging effects of substance p |
| 03/04/2009 | EP1635803B1 Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain |
| 03/04/2009 | EP1539738B1 Novel aryl- 4-halo-4- heteroarylmethylamino)-methyl -piperidin-1-yl -methanone derivatives, methods for production and use thereof as medicaments |
| 03/04/2009 | EP1506951B1 Method for the preparation of total salvianolic acid |
| 03/04/2009 | EP1490071B1 Therapeutic uses of sapogenins |
| 03/04/2009 | EP1485370B1 Amino-derivatives as novel inhibitors of histone deacetylase |
| 03/04/2009 | EP1472209B1 Lipoxin a4 analogs |
| 03/04/2009 | EP1455785B1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and the use of the same |
| 03/04/2009 | EP1452527B1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
| 03/04/2009 | EP1427720B1 3-substituted-4-pyrimidone derivatives |
| 03/04/2009 | EP1401863B1 Somatostatin-dopamine chimeric analogs |
| 03/04/2009 | EP1392312B1 TRIAZOLO 4,5-d PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS |
| 03/04/2009 | EP1380306B1 Remedies for restless leg syndrome |
| 03/04/2009 | EP1379269B1 Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson's disease |
| 03/04/2009 | EP1252322B2 Herpes virus strains for gene therapy |
| 03/04/2009 | EP1230243B1 Poycyloalkylpurines as adenosine receptor antagonists |
| 03/04/2009 | EP1146864B1 Ph independent extended release pharmaceutical formulation |
| 03/04/2009 | EP1140908B1 Triazole compounds with dopamine-d3-receptor affinity |
| 03/04/2009 | CN101379063A 3,9-diazabicyclo[3.3.1]nonane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 03/04/2009 | CN101379053A New citrate salt of an indole derivative and its pharmaceutical use |
| 03/04/2009 | CN101379043A Substituted 2-Aminopyrimidine-4-ones, their pharmaceutical compositions and their use in the treatment and/or prevention of ass-related pathologies |
| 03/04/2009 | CN101379042A Substituted cinnoline derivatives as GABAA-receptor modulators and method for their synthesis |
| 03/04/2009 | CN101379024A Process for manufacturing entacapone |
| 03/04/2009 | CN101378757A Thiadiazole derivatives for the treatment of neuro degenerative diseases |
| 03/04/2009 | CN101378751A Tuberous sclerosis treatment |
| 03/04/2009 | CN101378750A Indolone compounds useful to treat cognitive impairment |